Member Info for beinthelead

You think they are struggling or you don’t?

Quite a few on here have a lot to say. When it comes to sales, I’m content with the fact we have a test selling. Any opinions on sales figures are not worth their salt. We’ll get figures via RNS, if/when applicable.

Who says Avacta are struggling to sell? Pretty throwaway.

Zoom out. Their protein test is a product to enable the infrastructure of the business. Quality, logistics, manufacturing etc. How many have they actually sold?

Home use antigen testing is actually a thing. Green light market to open up the worlds economy. I think they target this, over a short term (weeks) market.

Simply not their market. Leave this to Calibre. Medusa will be popping in a few tests with an apparel delivery.

Good work. Thanks.

Watching - Impossible at the moment when the arguments are vacuous. I agree with you.

Ndn still hammering this CV issue on a daily basis, until he’s proven right. Then again, he uses Mologic as a shining beacon. Look where that’s got them to date.

Few trolls the past few weeks. And some on Twitter that hate the board, yet routinely view it to confirm they hate it so much. Bizarre, but there you go.

Anyway - This new rhetoric of, ‘go on, tell us why we should invest…’ is mental. Do not waste any of your time proving why these guys should hold onto an investment they despise so much.

We all have access to the RNS. Read, interpret. Believe or don’t. You pay your money…

Just another trader that floods this board with tripe, insults and repetitive negativity… oh no, wait, that must be another group.

Myles has cult status. To me he seems like a genuinely good, ethical bloke. I appreciate his insight, for sure. The majority of the people that mock him are generally bitter and jealous. It’s not a good luck - very unfair.

As far 85p next week. If it is? Why do you care? I’d move on and chill out a bit. It hurts being burnt by a share, I get that.

Good man :)

Block and report this guy. He is deplorable.

There’s much more to this government sales channel.

Our test will not pass PD’s validation. Yet we continue to talk about accessing their manufacturing capacity, and are still in ‘ongoing, but slow’ discussions.

Saliva collection - what gives?

Wow. But not unsurprising- the trial will be using a more accurate test. One capable of green light status. Innova/orient can’t achieve this level of performance. This is a good snippet. Not saying it’s AffiDx, but clear shift is apparent.

We’re way ahead of our starting point, mortgage. But I agree, the connections being made are admirable in terms of research, but can be quite wild.

Avacta are being blamed for most of these delays. Mologic’s lack of sales is a signal that there’s more to this than is being reported. Their test is very good. It should be selling, but isn’t. I don’t have the answer.

Our market will reveal itself soon, I’m sure. In the meantime it’s best to let things play out. Paralysis through analysis springs to mind.

These theories are starting to become a little far out.

It certainly my appears that way.

First class, it seems.

How can you ramp this stock a few weeks ago, when it was effectively at it lowest ebb in a while, yet return to bashing it now? Very odd

I’m sure the margin on Affimer supply is huge. Much higher than any other part of AffiDX. Don’t confuse margin with revenue.

Thanks ophidian. So as I thought, the tech, not AffiDX.